ArticleSexually transmitted diseases2016
Azithromycin Treatment Failure for Chlamydia trachomatis Among Heterosexual Men With Nongonococcal Urethritis.
Article in Sexually transmitted diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Coordinated topoisomerase function shapes the fluoroquinolone response ofMicrobiology spectrum · 2026Article
- Coordinated topoisomerase function shapes the fluoroquinolone response ofbioRxiv : the preprint server for biology · 2026Article
- Putative azithromycin resistance mutations inAntimicrobial agents and chemotherapy · 2026Article
- Post-treatment time to symptom resolution and associated factors in a cohort of Ugandan men with urethral discharge syndrome.BMC infectious diseases · 2025Article
- Design, Biological Evaluation, and Computer-Aided Analysis of Dihydrothiazepines as Selective Antichlamydial Agents.Journal of medicinal chemistry · 2023Article
- Sexually transmitted infections and female reproductive health.Nature microbiology · 2022Review
- Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Inhibition of the futalosine pathway for menaquinone biosynthesis suppresses Chlamydia trachomatis infection.FEBS letters · 2021Article
- Article
- Azithromycin combined with doxycycline in non-gonococcal urethritis.Experimental and therapeutic medicine · 2020Article
- PersistentInternational journal of STD & AIDS · 2020Article
- Epidemiology, molecular characterisation and antimicrobial susceptibility ofEpidemiology and infection · 2019Article
- Urogenital chlamydia trachomatis treatment failure with azithromycin: A meta-analysis.International journal of reproductive biomedicine · 2019Review
- A Synthetic, Small, Sulfated Agent Is a Promising Inhibitor ofFrontiers in microbiology · 2018Article
- Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents.Antimicrobial agents and chemotherapy · 2017Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThree recent prospective studies have suggested that the 1-g dose of azithromycin for Chlamydia trachomatis (Ct) was less effective than expected, reporting a wide range of treatment failure rates (5.8%-22.6%). Reasons for the disparate results could be attributed to geographic or methodological differences. The purpose of this study was to reexamine the studies and attempt to harmonize methodologies to reduce misclassification as a result of false positives from early test-of-cure (TOC) or reinfection as a result of sexual exposure rather than treatment failure.
methodsMen who had sex with women, who received 1-g azithromycin under directly observed therapy for presumptive treatment of nongonococcal urethritis with confirmed Ct were included. Baseline screening was performed on urethral swabs or urine, and TOC screening was performed on urine using nucleic acid amplification tests. Posttreatment vaginal sexual exposure was elicited at TOC. Data from the 3 studies were obtained and reanalyzed. Rates of Ct retest positive were examined for all cases, and a sensitivity analysis was conducted to either reclassify potential false positives/reinfections as negative or remove them from the analysis.
resultsThe crude treatment failure rate was 12.8% (31/242). The rate when potential false positives/reinfections were reclassified as negative was 6.2% (15/242) or when these were excluded from analysis was 10.9% (15/138).
conclusionsIn these samples of men who have sex with women with Ct-related nongonococcal urethritis, azithromycin treatment failure was between 6.2% and 12.8%. This range of failure is lower than previously published but higher than the desired World Health Organization's target chlamydia treatment failure rate of < 5%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.